What is the success rate of antibiotic therapy for acute otitis media (AOM) in a patient with no underlying medical conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Success Rate of Antibiotic Therapy for Acute Otitis Media

Antibiotic therapy for acute otitis media achieves clinical success in approximately 80-85% of patients by days 10-14, with treatment failure rates of 16-19% in young children when using stringent diagnostic criteria and appropriate antibiotics like high-dose amoxicillin-clavulanate. 1

Success Rates Based on Disease Severity and Age

Young Children (Under 2-3 Years) with Stringent AOM Diagnosis

The most robust data comes from recent trials using precise diagnostic criteria:

  • Unilateral AOM: Treatment success rate of 83% (failure rate 17.2%) with amoxicillin-clavulanate versus 57% with placebo (failure rate 42.7%) 1
  • Bilateral AOM: Treatment success rate of 78% (failure rate 21.7%) with amoxicillin-clavulanate versus 54% with placebo (failure rate 46.3%) 1
  • Overall success at day 10-12: 84% with antibiotics versus 49% with placebo (NNT = 2.9-3.8) 1

These studies demonstrate that when AOM is diagnosed with certainty (acute symptoms, middle ear effusion, and bulging/intensely erythematous tympanic membrane), the benefit of antibiotics is substantially greater than older studies suggested 1.

Comparison to Natural History

Approximately 50% of young children (younger than 2-3 years) experience clinical success when given placebo, but antibiotic therapy substantially improves outcomes with a number needed to treat (NNT) of 3-4 when otoscopic improvement is required, compared to NNT of 8-16 in older studies using less precise diagnostic criteria 1.

Success Rates by Antibiotic Choice

First-Line Therapy (Amoxicillin-Clavulanate)

  • High-dose amoxicillin-clavulanate (80-90 mg/kg/day): 81-84% success rate at days 10-14 1
  • Standard amoxicillin: Success rates vary but generally 76-88% depending on study population 2

Alternative Antibiotics

  • Azithromycin (3-day course): 83-89% clinical success at day 10-14, but only 74-75% sustained success at day 24-28 3
  • Ceftriaxone (single IM dose): 54-74% success rate at day 14, which is inferior to standard oral therapy (60-82% with comparators) 4
  • Azithromycin has high failure rates (20-25%) due to pneumococcal resistance and should be avoided as first-line therapy 5

Time Course of Treatment Success

Early Response (Days 4-5)

  • Treatment failure by day 4-5: 4% with antibiotics versus 23% with placebo 1

Standard Assessment (Days 10-14)

  • Treatment failure by day 10-14: 16-19% with antibiotics versus 44-51% with placebo 1

Long-Term Outcomes (Days 28-30)

  • By day 30, failure/recurrence rates equalize: 23-24% in both antibiotic and watchful waiting groups, indicating that many early failures eventually resolve 1
  • Sustained clinical success at day 24-28: 74-85% depending on antibiotic choice 3

Factors Affecting Success Rates

Age-Related Differences

Children under 2 years have lower success rates and benefit more from antibiotics (P = 0.008 for symptom resolution) 1

Disease Characteristics

  • Bilateral disease: Lower success rates than unilateral (78% vs 83% success) 1
  • Recent AOM episode (within preceding month): Significantly higher failure rates with short-course therapy 6

Treatment Duration

  • 5-day courses: 77% success rate overall, but inferior in children with recent AOM 2, 6
  • 10-day courses: 88% success rate, superior in otitis-prone children 2
  • Short-course antibiotics (less than 7 days): 21% failure rate versus 18% with standard courses (OR 1.34,95% CI 1.15-1.55) 7

Adverse Events Impact on Overall Success

Adverse events occur in 53% of antibiotic-treated patients versus 36% of placebo recipients (P = 0.003), primarily diarrhea and rash 1. This high rate of side effects must be weighed against the clinical benefit when determining overall treatment success from a quality-of-life perspective.

Critical Pitfalls

Diagnostic Precision Matters

Studies using less stringent diagnostic criteria (which may include otitis media with effusion, viral infections, or myringitis) show much lower antibiotic benefit (NNT 8-16) compared to studies with certain AOM diagnosis (NNT 3-4) 1. Ensure bulging tympanic membrane or intense erythema with middle ear effusion before initiating antibiotics.

Recurrence vs. Relapse

Most recurrent AOM episodes within 1 month (72%) are new infections, not true bacteriologic relapses 8. True relapses are most common in the first 7 days after treatment completion (41% of early recurrences) and decline thereafter 8.

Mastoiditis Risk

Antibiotics halve the risk of mastoiditis, but the NNT is approximately 4,800 patients to prevent one case, making universal antibiotic therapy impractical solely for mastoiditis prevention 1. However, 33-81% of mastoiditis cases occur despite prior antibiotic treatment, so failed therapy requires immediate reassessment 9.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Otomastoiditis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

A prospective observational study of 5-, 7-, and 10-day antibiotic treatment for acute otitis media.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2001

Research

Short-course antibiotics for acute otitis media.

The Cochrane database of systematic reviews, 2010

Guideline

Rate of Progression to Mastoiditis in Adults with Failed Treatment of Acute Otitis Media

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.